How effective is the generic version of Capmatinib from Laos No. 2 Factory?

Capmatinib (Capmatinib) The drug ingredients of the generic version of Capmatinib No. 2 in Laos are basically the same as those of the original drug. It has shown a certain degree of therapeutic effect in some clinical trials and has been approved by relevant regulatory agencies for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Capmatinib inhibits the growth and proliferation of tumor cells by specifically inhibiting the activity of MET tyrosine kinase and blocking the MET signaling pathway. MET is abnormally expressed in some cancer cells, leading to abnormal cell proliferation. Capmatinib's role is to interfere with this process and prevent further spread and spread of tumor cells.